Loading, please wait...Our presentation will start off with a case study to introduce the opportunity PGx can present, then we’ll get into a discussion of some background material, then information on the basics of pharmacogenomics; the ‘opportunity’; legislation; stakeholders; advantages and concerns; resources; a couple examples of medications where PGx can be applied; target markets; barriers and challenges; testing; and revisiting the case study to illustrate how to apply some of the materials discussed.
Activity Type
- Knowledge
Accreditation(s)
CPE Consultants, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education
|
|
|
|
Co-Sponsor(s)
PGx101
Our presentation will start off with a case study to introduce the opportunity PGx can present, then we’ll get into a discussion of some background material, then information on the basics of pharmacogenomics; the ‘opportunity’; legislation; stakeholders; advantages and concerns; resources; a couple examples of medications where PGx can be applied; target markets; barriers and challenges; testing; and revisiting the case study to illustrate how to apply some of the materials discussed.
Objectives
- To define general terms related to pharmacogenomics
- To describe the pharmacogenomic characteristics of codeine and clopidogrel
- To identify at least two resources that pharmacists might use to answer questions specific to PGx
- To describe challenges and opportunities with PGx testing
- To explain steps pharmacists can take to develop a pharmacogenomics service offering
Speaker(s)/Author(s)
|
Daniel Krinsky, MS, RPh |
|
|
Sue Paul, BSPharm
|
Activity Number
0864-0000-22-072-H99-P
Release Date:
Nov 11, 2022
Credit Expiration Date:
Nov 11, 2025
